Department of Pharmacy, Xi'an Chest Hospital, Xi'an, Shaanxi Province, China.
Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.
J Asthma. 2024 Sep;61(9):1068-1075. doi: 10.1080/02770903.2024.2324855. Epub 2024 Mar 12.
To evaluate the economic value of mepolizumab as an add-on therapy to the standard of care (SoC) for patients with severe eosinophilic asthma in China.
A Markov model with three health conditions was constructed to calculate the incremental cost per quality-adjusted life year (QALY) in mepolizumab with SoC and SoC only groups from the perspective of the Chinese healthcare system throughout an entire lifespan. The model was populated with local costs, while efficacy parameters were obtained from the global Phase III MENSA trial and mortality was derived from two surveys. One-way and probabilistic sensitivity analyses were conducted. Additional scenario analysis was used to estimate the cost-effectiveness impact of changes in the price of mepolizumab.
Over the lifetime treatment horizon, the incremental cost-effectiveness ratio (ICER) of mepolizumab plus SoC compared to SoC alone was $170 648.73 per QALY. Sensitivity analyses focused on these results. Scenario analysis showed that mepolizumab would require a price reduction of at least 82% to reach the current willingness-to-pay (WTP=$38 223.34/QALY) threshold.
Mepolizumab is not a cost-effective healthcare resource in China at its current pricing.
评估美泊利珠单抗作为重度嗜酸性粒细胞性哮喘患者标准治疗（SOC）附加疗法的经济价值。
采用 Markov 模型，构建了三种健康状况，从中国医疗保健系统的角度，在整个生命周期内计算美泊利珠单抗联合 SOC 治疗组和 SOC 单药治疗组每增加一个质量调整生命年（QALY）的增量成本。模型采用了当地成本，而疗效参数则来自全球 III 期 MENSA 试验，死亡率则来自两项调查。进行了单因素敏感性分析和概率敏感性分析。还进行了额外的情景分析，以估计美泊利珠单抗价格变化对成本效果的影响。
在整个治疗期间，美泊利珠单抗联合 SOC 治疗组与 SOC 单药治疗组相比，增量成本效果比（ICER）为每 QALY 170648.73 美元。敏感性分析主要集中在这些结果上。情景分析显示，美泊利珠单抗的价格至少需要降低 82%，才能达到当前的意愿支付（WTP）阈值（38223.34 美元/QALY）。
按照目前的定价，美泊利珠单抗在中国不是一种具有成本效益的医疗资源。
